FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations
On December 17, the US Food and Drug Administration approved blinatumomab for 72- and 96-hour infusion durations to offer more flexibility for physicians and their patients.
In Person Conference & ConventionJuly 18, 2026 at 3:30 PM CDT5005 Glumack Drive, Minneapolis, MN, USAInterContinental Hotel Minneapolis – St. Paul Airport, Minneapolis
